bharat biotech - Latest News, Analysis, Opinion

On Sunday Dr Krishna Ella, Executive Chairman, Bharat Biotech said that Bharat Biotech has started dispatching World's first Intranasal heterologous booster dose to hospitals

CCI Approves Bharat Biotech International-Eastman Exports Pact

National

The pact has been ratified under the green channel route, which means that a transaction that does not raise any risk of a noticeable unfavorable consequence on competition is considered to be approved

Centre Says Reports In Media Of Hasty Approvals For Bharat Biotech's Covaxin Are Misleading

Centre on Thursday said that media reports claiming that Bharat Biotech, manufacturer of the indigenous COVID-19 vaccine Covaxin, “had to skip certain processes” and “speed” up clinical trials due to political pressure are completely misleading, fallacious and ill-informed

Bharat Biotech's Intranasal Covid Vaccine Completes Phase III Trials

Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. The Centre partially funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha programme

Bharat Biotech Hopeful To Get Regulator's Nod For Intranasal Covid Vaccine

The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as booster dose. Separately, the DCGI also granted permission to the firm to conduct phase-3 clinical trial to compare the immunogenecity and safety of BBV-154 (intranasal) with Covaxin. This trial has been permitted to be conducted at nine sites

Bharat Biotech Expects To Get A Nod For Its Intranasal Covid-19 Vaccine By Aug

Health

The Drug Controller General approved the official trials on the intranasal Covid-19 vaccine and so the company is hopeful of getting regulatory licenses in August.

Covaxin Proven Safe For Children Of 2-18 Years Age Group In Phase III Study: Bharat Biotech

Bharat Biotech said in the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within one day. Pain at the injection site was the most commonly reported adverse event

Bharat Biotech Must Address Vaccine Issues Raised By WHO, Says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that Bharat Biotech addresses the issue immediately to avoid the cancellation

Covaxin Gets Emergency Use Authorisation For Children Aged 6-12: Sources

The development comes after the Subject Expert Committee (SEC) of the DCGI asked Bharat Biotech for additional data on Covaxin, for administering it to children aged between 2-12 years, sources said

Covaxin Booster Amplifies Protection Against Variants Of Concern: ICMR Study

As a part of the study the antibody responses in sera of 51 participants who received two doses of Covaxin collected six months post second dose and 28 days after receiving a third (booster) dose (given on day 215th post second dose) and its impact against the Omicron VoC was evaluated

Covishield And Covaxin Doses To Cost Rs 225 Now In Private Hospitals

The Serum Institute of India has cut the rates of Covishield from ₹600 to ₹225 per dose, while Bharat Biotech has brought down the price of Covaxin from ₹1,200 to ₹225

Bharat Biotech To Slow Down Covaxin Production

During the recent WHO post EUL inspection, the vaccine manufacturer agreed with the WHO team on the scope of the planned improvement activities and indicated that they will be executed as soon as practical

Bharat Biotech Says Supply Chains Not Impacted By Russia-Ukraine Conflict

Companies & Markets

A few Indian pharmaceutical companies have a presence in Russia, exporting and selling medicines in the country. Sales to Russia between April and December last year reached $386 million, or 15% of the total exports to the country

Govt Expert Panel Recommends Regular Market Approval For Covishield, Covaxin